Lumena swings for a $75M IPO to bear down on liver diseases

Fierce Biotech
April 3, 2014
Damian Garde

A month removed from raising $45 million in venture backing, San Diego’s Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments.  Read More

Read More

RiverVest Venture Partners Promotes Niall O’Donnell to Managing Director; Michael Berman Joins as Venture Partner

ST. LOUIS (April 2, 2014) – RiverVest Venture Partners today announced the promotion of Niall O’Donnell, Ph.D., to Managing Director. The life sciences venture capital firm also announced that medical device entrepreneur Mike Berman, a long-time member of RiverVest’s Scientific & Industry Advisory Board, has joined the firm as Venture Partner.

Read More

“The Frank Drebin Approach to Healthcare”

“The Frank Drebin Approach to Healthcare” by RiverVest’s Niall O’Donnell, appearing in the Rady Business Journal, a Publication of the Rady School of Management. University of California, San Diego. Winter, 2014.  Read more

Read More

ZS Pharma Announces Start of Enrollment of Phase 3 Extended Dosing Study of ZS-9 in Patients with Hyperkalemia

Coppell, Texas – March 25, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.

Read More
Led Verlichting . . saffron extract